Refined Disease Risk Index for Hematological Malignancies, Including Rare Disorders, After Allogeneic Stem Cell Transplantation

Fujiwara, Shun; Hattori, Norimichi; Matsui, Tomoharu; Nakata, Ayaka; Sasaki, Yohei; Shimada, Shotaro; Murai, So; Abe, Maasa; Baba, Yuta; Watanuki, Megumi; Kawaguchi, Yukiko; Arai, Nana; Kabasawa, Nobuyuki; Tsukamoto, Hiroyuki; Uto, Yui; Yanagisawa, Kouji; Harada, Hiroshi; Nakamaki, Tsuyoshi

doi:10.1016/j.transproceed.2019.08.044

Cited by 9 publications

(6 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To assess and compare the transplant risk to the populations, we measured the EBMT risk score together with the definition of early versus advanced disease. [18][19][20] The acute GVHD II-IV, acute GVHD III-IV, and chronic GVHD (evaluated as a whole without distinguishing between limited and extensive) cumulative incidences were calculated using NCSS software. The competing risks for GvHDs were relapse and death in remission.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

HSCT with mismatched unrelated donors: Bone marrow versus peripheral blood stem cells sources in pediatric patients

Berger

Barone

Spadea

et al. 2022

Pediatric Transplantation

View full text Add to dashboard Cite

Hematopoietic stem cell transplantation (HSCT) remains the only curative option for many patients with hematologic malignancies.The best donor for HSCT is an identical human leukocyte antigen (HLA) graft from a matched related donor (MRD) or matched unrelated donor (MUD). Unfortunately, because of the average family size in Italy, less than 30% of patients will have an MRD 1 and strategies to identify alternative stem cell sources in the absence of a MUD are, therefore, needed. Currently, a commonly used strategy

show abstract

Section: Discussionmentioning

confidence: 99%

“…To assess and compare the transplant risk to the populations, we measured the EBMT risk score together with the definition of early versus advanced disease 18–20 …”

Section: Methodsmentioning

confidence: 99%

HSCT with mismatched unrelated donors: Bone marrow versus peripheral blood stem cells sources in pediatric patients

Berger

Barone

Spadea

et al. 2022

Pediatric Transplantation

View full text Add to dashboard Cite

show abstract

“…Relapse was defined as the reappearance of tumor cells at any site. To assess and compare the transplant risk of these populations we measured the DRI and EBMT risk scores for all the patients [27][28][29].…”

Section: Discussionmentioning

confidence: 99%

“…Table 1 describes the main clinical characteristics of the study population. All patients underwent their first allogeneic HSCT and there were evidently significant differences at the baseline between the groups: (1) the patients' age was more advanced in the ATG group, (2) an intermediate to high disease risk index (DRI) [27,28] was more present in the ATG group, (3) the interval between diagnosis and HSCT was greater in the PT-Cy group, (4) TBI was mostly chosen in the ATG group, and (5) a reduced intensity regimen (RIC) was more frequently chosen in the ATG group. The European Blood and Marrow Transplant (EBMT) [29] scores did not differ among the groups.…”

Section: Methodsmentioning

confidence: 99%

“…Three-year RI for the entire population was 21% (95%, CI [15][16][17][18][19][20][21][22][23][24][25][26][27][28][29], in particular, it was 15% vs. 28% (p = NS) for the ATG and PT-Cy groups, respectively. As reported in Table 2, the univariate analysis showed that the following factors had a statistically significant effect on RI: higher DRI (p = 0.015) and higher EBMT score (p < 0.00001).…”

Section: Relapse Incidencementioning

confidence: 99%

See 1 more Smart Citation

HSCT with Mismatched Unrelated Donors (MMUD): A Comparison of Different Platforms for GvHD Prophylaxis

et al. 2022

View full text Add to dashboard Cite

HSCT from an unrelated HLA-mismatched donor (MMUD) is one of the alternatives where an HLA-matched donor is not found. The aim of this study was to compare GvHD prophylaxis with anti-thymocyte globulin (ATG) vs. post-transplant cyclophosphamide (PT-Cy). Thirty-nine adult patients were uniformly treated with rabbit ATG-Cy-A-MTX and peripheral blood stem cell (PBSC) and 40 adult patients with PT-Cy-MMF-tacrolimus and PBSC. This retrospective study was registered at ClinicalTrials.gov NCT04598789. Three-year overall survival was 42% vs. 64% for ATG and PT-Cy (p < 0.0005), three-year treatment-related mortality (TRM) was 36% vs. 8% (p = 0.0033) and the three-year relapse incidence (RI) was 15% vs. 28% (p = NS), respectively. The incidences of day-100 GvHD graded II–IV and III–IV were 39% vs. 7% (p = 0.0006) and 11% vs. 0% (p = 0.04), respectively, whereas the three-year cGvHD incidences were 48% vs. 13% (p = 0.0005), respectively. We were able to show how PT-Cy can reduce the incidence of GvHDs and TRM in adults, but relapse remains an issue.

show abstract

Immune reconstitution and survival of patients with parvovirus B19 related pure red cell aplasia after haplo-PBSCT

et al. 2022

View full text Add to dashboard Cite

Parvovirus B19 (PvB19) infection and PvB19 related pure red cell aplasia (PRCA) in recipients with allogeneic hematopoietic stem cell transplantation have been reported sporadically. However, clinical studies with large sample sizes are lacking, especially in patients undergoing HLA-haploidentical peripheral blood stem cell transplantation (haplo-PBSCT). In addition, clinical features, immune reconstitution, and outcomes of these patients are not clear. We conducted a retrospective analysis of 164 patients who received haplo-PBSCT with low-dose anti-thymocyte globulin (ATG) plus low-dose posttransplant cyclophosphamide (PTCy)-based regimen as graft-versus-host disease (GVHD) prophylaxis. We analyzed the incidence of PvB19 related PRCA and compared the clinical characteristics, immune reconstitution, incidence of GVHD, relapse rate, and survival between patients with and without PvB19 related PRCA. A total of 14 (8.5%) recipients developed PvB19 related PRCA after a median of 5.3 months after haplo-PBSCT. These patients with PvB19 related PRCA had slower immune reconstitution, but similar incidences of GVHD, relapse rate, and overall survival compared with recipients without PvB19 related PRCA. PvB19 related PRCA indicated relative delayed and poor immune reconstitution of the recipients early after haplo-PBSCT. PvB19 related PRCA had no effects on GVHD, relapse, and survival.

show abstract

Refined Disease Risk Index for Hematological Malignancies, Including Rare Disorders, After Allogeneic Stem Cell Transplantation

Cited by 9 publications

References 18 publications

HSCT with mismatched unrelated donors: Bone marrow versus peripheral blood stem cells sources in pediatric patients

HSCT with mismatched unrelated donors: Bone marrow versus peripheral blood stem cells sources in pediatric patients

HSCT with Mismatched Unrelated Donors (MMUD): A Comparison of Different Platforms for GvHD Prophylaxis

Immune reconstitution and survival of patients with parvovirus B19 related pure red cell aplasia after haplo-PBSCT

Contact Info

Product

Resources

About